Clinical trial Recruiting at 1 site Interventional Ages 18 to 60

Intensive versus standard cholesterol lowering to slow coronary plaque in young and middle-aged adults with chronic coronary syndrome

Official title: Coronary Computed Tomography Study to Assess the Effect of Intensive Lipid-Lowering Therapy on Coronary Atherosclerotic Plaque Progression in Young and Middle-Aged Patients With Chronic Coronary Syndrome: A Nationwide, Multicentre, Randomized Controlled Trial

Run by Guangdong Provincial People's Hospital · NCT06896708 · Data updated 2026-11-12

This trial will test whether more intensive cholesterol lowering (LDL-C <1.0 mmol/L) compared with guideline-level lowering (LDL-C <1.8 mmol/L) can slow or reverse coronary plaque in adults 18–60 with chronic coronary syndrome and a 50–70% lesion on CCTA.

Quick facts

Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment766 (estimated)
SponsorGuangdong Provincial People's Hospital
Academic / other
Locations7 sites (Chongqing, Chongqing Municipality and 6 other locations)
StatusRecruiting
StartedAugust 12, 2025
Main results expectedJuly 1, 2027
Study endsMarch 1, 2028
Registry record updatedDecember 17, 2025
Trial IDNCT06896708 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults 18–60 years old with chronic coronary syndrome managed without intervention, at least one CCTA-identified 50–70% coronary lesion, and baseline LDL-C levels meeting the trial's entry criteria (on statin with LDL-C ≥1.8 mmol/L or statin-naive with LDL-C ≥2.6 mmol/L).

Probably not a fit

Patients with left main or severe three-vessel disease, ultra-high-risk ASCVD, familial hypercholesterolemia, very high baseline LDL-C above the trial cutoffs, recent PCSK9/ezetimibe use, or those who do not meet the CCTA lesion criteria are unlikely to benefit from this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter, open-label, randomized, parallel-group trial enrolling adults aged 18–60 with chronic coronary syndrome managed without revascularization and at least one 50–70% stenosis identified by coronary CT angiography (CCTA). Participants are randomized to an intensive lipid-lowering strategy targeting LDL-C <1.0 mmol/L and ≥50% reduction from baseline or to a guideline-directed strategy targeting LDL-C <1.8 mmol/L and ≥50% reduction. Coronary plaque volume and characteristics are quantified noninvasively by serial CCTA to compare plaque progression between groups. The trial examines whether deeper LDL-C reduction leads to greater plaque stabilization or regression in this younger patient population.

Why it matters

Potential benefit: If successful, more intensive LDL lowering could slow or reverse coronary plaque progression and may reduce future heart attack risk in younger adults with chronic coronary syndrome.

How similar studies have gone: Previous imaging and outcome studies have shown that lower LDL-C levels are associated with slower plaque progression and more regression, but randomized data specifically testing LDL-C targets below 1.0 mmol/L in young and middle-aged CCS patients are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1\. Aged 18-60 years at screening 2. Stable angina symptoms with suspected or confirmed coronary artery disease; 2. CCTA examination demonstrating: at least one major coronary artery with a diameter of ≥1.5mm that has not been intervened and at least one leision with 50%-70% stenosis.

3\. Subjects who have been using statin therapy alone for at least 4 weeks prior to enrollment with a baseline LDL-C ≥1.8mmol/L or subjects who have not initiated lipid-lowering therapy prior to enrollment with a baseline LDL-C≥2.6mmol/L.

Exclusion Criteria:

1. Left main coronary artery disease or severe three-vessel disease;
2. Ultra-high-risk ASCVD patients: ≥2 severe ASCVD events or 1 severe ASCVD event with ≥2 high-risk factors;
3. Use of PCSK9 inhibitors or ezetimibe within 8 weeks prior to study enrollment;
4. The baseline LDL-C was relatively high (LDL-C≥2.6 mmol/L in those taking statins and ≥4.9 mmol/L in those not taking statins).
5. Familial hypercholesterolemia;
6. Known allergy/intolerance to lipid-lowering drugs used in the trial;
7. Patients with severe congestive heart failure, liver or kidney dysfunction, or malignancy;
8. Pregnant or breastfeeding female patients.

Where it's running

  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
  • The First Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
    Not yet recruiting
  • The Ninth Clinical Medical College of Guangzhou University of Chinese Medicine
    Dongguan, Guangdong, China
    Not yet recruiting
  • The Third Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong, China
    Not yet recruiting
  • The Eighth Affiliated Hospital of Sun Yat-sen University
    Shenzhen, Guangdong, China
    Not yet recruiting
  • Zhongshan People's Hospital
    Zhongshan, Guangdong, China
    Not yet recruiting
Show 1 more location
  • The First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning, China
    Not yet recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.